Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 27;11(3):330-334.
doi: 10.4254/wjh.v11.i3.330.

Persistent elevation of fibrosis biomarker cartilage oligomeric matrix protein following hepatitis C virus eradication

Kristofer Andréasson  1 , Göran Jönsson  2 , Roger Hesselstrand  3 , Hans Norrgren  2
Affiliations

Persistent elevation of fibrosis biomarker cartilage oligomeric matrix protein following hepatitis C virus eradication

Kristofer Andréasson et al. World J Hepatol. .

Abstract

Serum levels of cartilage oligomeric matrix protein (COMP) has been presented as a biomarker of liver fibrosis in several cross-sectional studies. COMP is also an essential mediator in carcinoma development and has also been associated with hepatocellular carcinoma. We present a prospective analysis of this biomarker in 38 patients with chronic hepatitis C who were subject to eradication therapy with direct acting antivirals. We confirm previous studies associating COMP elevation with liver cirrhosis. We also show how viral levels are correlated with COMP at baseline. In our prospective analysis, we report that successful eradication of hepatitis C results in improvement in liver stiffness and laboratory liver function tests at 1 year follow-up. In contrast, median COMP-levels remain unchanged during the study period. We conclude that the biomarker potential of COMP in the prospective evaluation of liver diseases, remains to be elucidated.

Keywords: Cartilage oligomeric matrix protein; Chronic; Fibrosis; Hepatitis C.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

Figures

Figure 1
Figure 1
Direct acting antiviral agents-induced sustain viral response is associated with improvements in liver stiffness, aspartate aminotransferase platelet ratio index but not in S-cartilage oligomeric matrix protein. Box-plots on measurements of liver stiffness (A), aspartate aminotransferase platelet ratio index (B) and S-cartilage oligomeric matrix protein (C), made at baseline (A-C), 4 wk of treatment (B and C), at end of treatment (B and C) and at 1-2 years follow up (A-C). Center lines show the medians; box limits indicate the 25th and 75th percentiles as determined by R software[12]; whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles, outliers are represented by dots; data points are plotted as open circles. n = 38 for all measurements. APRI: Aspartate aminotransferase platelet ratio index; COMP: Cartilage oligomeric matrix protein; EOT: End of treatment.
See this image and copyright information in PMC

References

    1. Vermehren J, Park JS, Jacobson IM, Zeuzem S. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol. 2018;69:1178–1187. doi: 10.1016/j.jhep.2018.07.002. - DOI - PubMed
    1. Miyaki E, Imamura M, Hiraga N, Murakami E, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Aikata H, Hayes CN, Chayama K. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. Hepatol Res. 2016;46:758–764. doi: 10.1111/hepr.12621. - DOI - PubMed
    1. Crnkic M, Månsson B, Larsson L, Geborek P, Heinegård D, Saxne T. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res Ther. 2003;5:R181–R185. doi: 10.1186/ar760. - DOI - PMC - PubMed
    1. Li M, Lu S, Liu X, Zhao J, Zhang H, Ling C. [Expression of endoglin in human non-small cell lung cancer and its clinical significance] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013;29:581–584. doi: 10.1242/jcs.180216. - DOI - PubMed
    1. Norman GL, Gatselis NK, Shums Z, Liaskos C, Bogdanos DP, Koukoulis GK, Dalekos GN. Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma. World J Hepatol. 2015;7:1875–1883. doi: 10.4254/wjh.v7.i14.1875. - DOI - PMC - PubMed